1. Home
  2. HXL vs TGTX Comparison

HXL vs TGTX Comparison

Compare HXL & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hexcel Corporation

HXL

Hexcel Corporation

HOLD

Current Price

$90.65

Market Cap

7.8B

Sector

Industrials

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$54.68

Market Cap

7.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HXL
TGTX
Founded
1946
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.8B
7.9B
IPO Year
1994
2008

Fundamental Metrics

Financial Performance
Metric
HXL
TGTX
Price
$90.65
$54.68
Analyst Decision
Buy
Strong Buy
Analyst Count
10
5
Target Price
$88.30
$49.80
AVG Volume (30 Days)
627.6K
1.8M
Earning Date
04-22-2026
05-04-2026
Dividend Yield
0.80%
N/A
EPS Growth
N/A
1746.67
EPS
N/A
0.17
Revenue
$1,893,900,000.00
$2,785,000.00
Revenue This Year
$10.09
$49.08
Revenue Next Year
$12.33
$26.69
P/E Ratio
N/A
$326.94
Revenue Growth
N/A
N/A
52 Week Low
$60.26
$26.76
52 Week High
$111.74
$59.30

Technical Indicators

Market Signals
Indicator
HXL
TGTX
Relative Strength Index (RSI) 31.09 59.68
Support Level $88.83 $51.51
Resistance Level $92.59 $58.04
Average True Range (ATR) 2.24 2.70
MACD -0.30 0.29
Stochastic Oscillator 10.28 78.59

Price Performance

Historical Comparison
HXL
TGTX

About HXL Hexcel Corporation

Founded in 1948, Hexcel designs and manufactures a range of highly engineered composite fibers, fabrics, resins, and structures for use primarily in the commercial aerospace and defense markets. These are lighter than metal and perform under rigorous conditions in aircraft frames, wings, engine nacelles, and other structures and subassemblies. The company's name derives from the six-sided honeycomb structures that lend many of its products their light weight and rigidity. Hexcel's biggest customers are Airbus (40% of 2024 sales) and Boeing (15% of 2024 sales; 25% before the pandemic) and their respective subcontractors.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: